CG
DMK

Cutler Group’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Cutler Group’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-92
Closed -$14K – 4926
2018
Q4 		$14K Sell
92
-8
-8% -$1.53K ﹤0.01% 2365
2018
Q3 		$24K Buy
100
+96
+2,400% +$22.7K ﹤0.01% 2131
2018
Q2 		$0 Sell
4
-8
-67% -$2.14K ﹤0.01% 5079
2018
Q1 		$3K Sell
12
-32
-73% -$8.4K ﹤0.01% 3648
2017
Q4 		$13K Buy
44
+32
+267% +$10.5K ﹤0.01% 2940
2017
Q3 		$4K Sell
12
-27
-69% -$9.6K ﹤0.01% 4667
2017
Q2 		$14K Buy
39
+18
+86% +$5.39K ﹤0.01% 3837
2017
Q1 		$6K Buy
21
+15
+250% +$3.78K ﹤0.01% 4617
2016
Q4 		$1K Hold
6
– – ﹤0.01% 6219
2016
Q3 		$1K Sell
6
-95
-94% -$19.7K ﹤0.01% 6373
2016
Q2 		$19K Buy
101
+74
+274% +$34.1K ﹤0.01% 3437
2016
Q1 		$11K Buy
+27
New +$9.6K ﹤0.01% 3977

Other funds holding DMK

First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Bard Associates
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

Cutler Group's DMK Position: Q1 2019 in Review

Cutler Group sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2019, closing a stake of 92 shares — an estimated $14K sold.

Cutler Group first reported a position in DMK in Q1 2016 and held it in 12 quarters. The position peaked at $24K in Q3 2018. 57 funds tracked by Wall St. Rank hold DMK as of Q1 2019.

  • Cutler Group reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2019 after selling out during the quarter.
  • Cutler Group sold 92 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2019, an estimated $14K.
  • Cutler Group first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2016 and held it in 12 quarters.
  • Cutler Group's DMK Pharmaceuticals Corporation Common Stock position peaked at $24K in Q3 2018.
  • 57 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2019.

Based on Cutler Group's 13F filing for Q1 2019, filed 10 May 2019.